Eli Lilly And Co vs Trip.com Group Ltd — how do they compare? Eli Lilly And Co trades at $1,214.9 (market cap $1.10T), while Trip.com Group Ltd trades at $45.65 (market cap $29.26B). The key difference: Eli Lilly And Co is far larger — about 37.6× Trip.com Group Ltd's market cap, and Eli Lilly And Co pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| LLY | TCOM | |
|---|---|---|
Market Cap | $1.10T | $29.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $78.96 |
52-Week Low | $639.43 | $39.84 |
Enterprise Value | $1.14T | $21.91B |
Dividend Yield | 0.56% | 0.42% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
TCOM trades at $46.14, down 0.22% on the day, with a neutral technical signal and bearish moving averages. The company reported strong 2025 revenue of $62.41B and net income of $33.29B, with high profitability margins. Recent news includes a $770M antitrust penalty in China, impacting sentiment, while Q2 2026 earnings are expected at $0.873 per share.
Outlook remains mixed: strong fundamentals and a consensus price target of $59.29 suggest upside, but regulatory risks and recent earnings misses pose challenges. The stock offers value with a low P/E of 6.88, yet investors must weigh growth sustainability against antitrust pressures and guidance concerns.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →